Trade in Counterfeit Pharmaceutical Products / Organisation for Economic Co-operation and Development and European Union Intellectual Property Office

Format:

Book

Government document

Author/Creator:

Organisation for Economic Co-operation and Development.

Contributor:

European Union Intellectual Property Office.

Series:

Illicit Trade, 26175835.

Language:

English

Subjects (All):

Governance.

Trade.

Local Subjects:

Governance.

Trade.

Physical Description:

1 online resource (94 p. )

Place of Publication:

Paris : OECD Publishing, 2020.

Summary:

This report, one in a series of studies by the OECD and the European Union Intellectual Property Office (EUIPO), enhances understanding of the issues and challenges facing governments, businesses and society posed by the trade in fake pharmaceutical products. Illicit markets for fake pharmaceuticals are attractive for counterfeiters, given the high profit margins, low risks of detection and prosecution, weak penalties, and the ease with which consumers can be deceived into believing that the counterfeit products are genuine. Counterfeit medicines not only cause economic damage for the sector, but are also a significant threat to public health, since fake medicines are often not properly formulated and may contain dangerous ingredients. Fake pharmaceuticals include antibiotics, lifestyle treatments, pain killers, anti-malarial drugs, diabetes treatments and central nervous system medicines.

Contents:

Introduction

Executive Summary

Preface

Additional Tables

Concluding remarks

Mapping the scale of the fake pharmaceutical challenge

The push factors behind counterfeit pharmaceuticals

Impact of counterfeit medicines

Counterfeit pharmaceuticals: scope and data

Acronyms and abbreviations

The supply chain: marketing, transport and distribution

Efforts to combat counterfeit pharmaceuticals

Industry overview

Data and methodology

Foreword.

ISBN:

9789264769465

9264769463